Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Table 3 Scheme dose, adverse events and discontinuation rate of first and second line tyrosine kinase inhibitors and anti-vascular-endothelial growth factor agents approved for the treatment of advanced hepatocellular carcinoma

Study drug	Dose reduction - interruption	Discontinuation rate
Sorafenib	26% dose reduction (any AE), 44% drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction and rash	11%
Lenvatinib	37% dose reduction (related-AE), 40% drug interruption (related-AE), Most frequent AE leading to dose reductions: not reported	9%
Regorafenib	68% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction	10%
Cabozantinib	62% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction	16%
Ramucirumab	34% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: fatigue, peripheral edema, hypertension and anorexia	11%

Comparison across studies should cautiously analyzed. AE: Adverse event.